SI
ITRM

Sofinnova Investments’s Iterum Therapeutics ITRM Stock Holding History

Sofinnova Investments’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-115,101
Closed -$4.68M – 86
2020
Q1 		$4.68M Hold
115,101
– – 0.43% 35
2019
Q4 		$7.77M Hold
115,101
– – 0.56% 37
2019
Q3 		$9.96M Hold
115,101
– – 0.9% 26
2019
Q2 		$11.9M Hold
115,101
– – 1.09% 21
2019
Q1 		$13.7M Hold
115,101
– – 1.32% 15
2018
Q4 		$8.65M Hold
115,101
– – 1.08% 23
2018
Q3 		$11.4M Hold
115,101
– – 1.02% 19
2018
Q2 		$18.8M Buy
+115,101
New +$20.8M 2.13% 10

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.22B AUM 16.98% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $108M AUM 54.47% 1-Year Est. Return

Sofinnova Investments's ITRM Position: Q2 2020 in Review

Sofinnova Investments sold out of Iterum Therapeutics (ITRM) in Q2 2020, closing a stake of 115,101 shares — an estimated $4.68M sold.

Sofinnova Investments first reported a position in ITRM in Q2 2018 and held it in 8 quarters. The position peaked at $18.8M in Q2 2018. 10 funds tracked by Wall St. Rank hold ITRM as of Q2 2020.

  • Sofinnova Investments reported no remaining Iterum Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Sofinnova Investments sold 115,101 Iterum Therapeutics shares in Q2 2020, an estimated $4.68M.
  • Sofinnova Investments first reported a position in Iterum Therapeutics in Q2 2018 and held it in 8 quarters.
  • Sofinnova Investments's Iterum Therapeutics position peaked at $18.8M in Q2 2018.
  • 10 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2020.

Based on Sofinnova Investments's 13F filing for Q2 2020, filed 13 Aug 2020.